Twenty-two drugs have voluntarily withdrawn their networks and withdrawn from the market in major pharmaceutical provinces

"Pharmaceutical Network Industry Dynamics" September 14, Guizhou Province Public Resources Trading Center issued a notice to cancel some of the drug winning bid (hanging net) qualification notice.
Among them, 22 drugs were disqualified from winning the bid (hanging net), and are basically large varieties, including injection of antonin, cephalosporinecapsules, raw pulse drinks, involving Taiji Group Chongqing Chinese Medicine Co., Ltd., Southwest Pharmaceutical Co., Ltd., Suzhou Second Leaf Pharmaceutical Co., Ltd. and other well-known pharmaceutical companies.
It is worth noting that according to the documents, some enterprises are due to production line transformation, production stoppage and other reasons, resulting in drugs can not guarantee the supply, only submitted on the cancellation of their products in Guizhou Province drug centralized procurement of the winning bid (hanging net) qualification application, and promised that from the date of cancellation, the enterprise with the same product regulations products for two years not to participate in the centralized procurement activities of drugs in Guizhou Province.
but industry insiders said, in fact, look at these products, you can find that the real reason for the company's shutdown, or not sell well, limited market share, or profit is not high.
for enterprises, once the cost of production increases, these products, belong to the "chicken ribs", so the survival of the fittest, it is normal.
, in fact, recently, pharmaceutical companies have taken the initiative to apply for the withdrawal of the network of frequent incidents, has been a large number of drug production, stop supply.
January 8,
, Hainan Province Pharmaceutical Centralized Purchasing Center issued the "Notice on the publicity of some drug withdrawal network (2020.01.08)," there are 250 drug applications to cancel the network.
Of these, 171 drugs were discontinued due to rising production costs, inability to supply normally, line modifications, production line stops, etc., 28 drugs were discontinued due to price increases or shortages of API, and 15 drugs were discontinued due to the upside-down price and cost of the winning bid.
April 23, Hainan Province Public Resources Trading Service Center also issued "on the public notice of the part of the new hanging network and withdrawal of drug information", the notice mentioned that the qupibutong tablets, lithium carbonate tablets, sodium heparin injection, hydrochloric acid bubica injection 5 drugs due to rising costs, apply for removal of the network.
addition, Jiangsu, Fujian and other places have also appeared in the enterprise initiative to scrap the mark or withdraw the network situation.
May 25, Shanxi Province, the centralized bidding procurement network hung two notices, including Chenxin Pharmaceuticals, Chengdu Deo Pharmaceutical Group, Shi Pharmaceutical Group, Ha Pharmaceutical Group, Shenwei Pharmaceuticals and other 25 enterprises also because of rising costs, apply for the withdrawal of the network.
addition to the 66 drug regulations involved, enterprises also make a unified national commitment not to supply.
, such as sodium chloride injections, double yellow-linked particles, etc.
From the above comprehensive point of view, most pharmaceutical companies will withdraw products from the market the root cause, mainly due to the recent drug review and approval system reform to encourage drug innovation, with volume procurement squeeze dry intermediate link moisture, cut off the gold sales chain, consistent evaluation to promote generic clinical replacement of high-priced original drugs, as well as focus on monitoring and strengthening clinical rational drug use policies, China's pharmaceutical market pattern is changing dramatically.
and coupled with rising production costs, raw material costs and other prices, many enterprises in the production process of some small-scale varieties of the cost of upside down and other phenomena, resulting in a large number of drugs abandoned, pharmaceutical companies were forced to abandon the market.
But no matter what the reason, the current national collection, provincial collection and local collection of three layers of nested power, drug price reduction, generic drug shuffle has been an inevitable trend.
This shows that the cost control ability of enterprises will largely determine its development prospects, but also means that in the future, the cost control ability is strong, the core variety is large, the market share is high, by virtue of cost advantage to seize the market enterprises, or easier to survive, and become the direction of enterprise transformation.